Becketts advises Telix Pharmaceuticals on acquisition of ARTMS Inc. (Canada)

Telix is an ASX-listed (ASX: TLX) biopharmaceuticals company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe and Japan.

ARTMS Inc is a radioisotope production technology firm based in Vancouver, British Columbia.  As part of the transaction, Telix also acquired ARTMS’s advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure radio-metals required for consumable target production.

The Becketts team which advised Telix on the transaction included Alex Bean and Nick Golding, Partners, and Brad Papaluca, Lawyer. Telix’s Canadian lawyers on the transaction were Aird & Berlis LLP, with the team led by David Takenaka, Partner and Ian McLeod, Associate.